Phase III Clinical Study of AJG522 : Studies of safety and efficacy of AJG522 as a colon preparation agent for colonoscopy - Comparative study with MGV-5
Phase 3
- Conditions
- Patients scheduled for colonoscopy
- Registration Number
- JPRN-jRCT2080221438
- Lead Sponsor
- Ajinomoto Pharmaceuticals Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients scheduled for colonoscopy.
Exclusion Criteria
- Presence or suspicion of gastrointesinal ileus, intestinal perforation or toxic megacolon.
- Renal impairment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Colon cleansing effect.<br>Colon cleansing effect will be assessed by the colonoscopy.
- Secondary Outcome Measures
Name Time Method Dosage of investigational product administration<br>Cleansing time